In the field of surgical treatment for breast cancer, the trend of "de-escalation" in axillary management has become a consensus. Although studies such as ACOSOG Z011 and AMAROS have laid the foundation for exempting axillary lymph node dissection (ALND) in patients with positive sentinel lymph nodes (SLN), controversy remains in clinical practice regarding whether it is safe to exempt ALND for patients undergoing total mastectomy, patients with large tumors (T3), and those with macrometastases. At this conference, Professor Jana de Boniface from Karolinska Institutet and Capio St. Göran Hospital in Sweden presented the highly anticipated latest results of the SENOMAC trial, a randomized controlled study focusing on survival data and patient-reported arm complications after exempting ALND in patients with SLN macrometastases.

At a recent international breast cancer academic conference, Professor Nicholas C. Turner from The Royal Marsden Hospital and the Institute of Cancer Research (ICR) in the UK presented the highly anticipated primary analysis results of the Phase III persevERA BC study. This study aimed to evaluate the efficacy and safety of a novel oral selective estrogen receptor degrader (SERD), Giredestrant (GIRE), in combination with the CDK4/6 inhibitor Palbociclib (PALBO), compared to the standard aromatase inhibitor (AI) Letrozole (LET) plus Palbociclib, in the first-line treatment of estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in grand fashion in Chicago, showcasing numerous highlights and breakthroughs in gastrointestinal oncology. On this occasion, Oncology Frontier invited Prof. Yinying Wu from the First Affiliated Hospital of Xi’an Jiaotong University to share her perspectives and discuss the impressive contributions of Chinese investigator-initiated research presented at this year’s meeting.

Following the successful online sessions held during the first three days of the CGOG Annual Meeting, including six ASCO Highlights sessions and six thematic symposia, the on-site program officially commenced on June 12. On Day 4 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting, two parallel forums attracted strong interest from attendees. The Precision Translational Medicine Forum brought together experts from a wide range of academic disciplines for in-depth exchange and discussion.

Following the successful completion of six ASCO Highlights sessions and six thematic symposia during the first three days of the CGOG Annual Meeting, the conference transitioned to its in-person program…

The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.

In the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, the choice of chemotherapy regimen, timing of administration (neoadjuvant vs. adjuvant), and optimization of dose density remain focal points of clinical debate for biologically high-risk patients. In a recent academic conference, Professor Oleg Gluz from the West German Study Group (WSG) shared pooled analysis data from the WSG ADAPT-HR+/HER2- and PlanB studies. This analysis focused on a high-risk population with a Recurrence Score (RS) >25 or lymph node positivity (>4), aiming to explore the impact of different chemotherapy strategies on long-term patient survival.

At the recent 2026 ASCO Annual Meeting, Professor Peter Schmid, representing the lidERA study group from the Barts Cancer Institute, Queen Mary University of London, detailed the efficacy and safety analysis results based on menopausal status (pre/perimenopausal vs. postmenopausal) from the Phase III lidERA BC clinical trial. The study aims to evaluate the clinical value of Giredestrant (GIRE), a next-generation oral selective estrogen receptor degrader (SERD), in the adjuvant treatment of patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer (eBC).

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Sara M. Tolaney from Dana-Farber Cancer Institute and Harvard Medical School, representing the research team, presented the latest exploratory analysis results of the ASCENT-04 study (NCT04612127). This analysis delved into the impact of biomarkers—Trop-2 expression levels, BRCA mutation status, and HER2 expression status—on the efficacy of Sacituzumab Govitecan (SG) combined with Pembrolizumab as a first-line treatment for PD-L1 positive metastatic triple-negative breast cancer (mTNBC), providing key evidence for the precise selection of benefited populations in clinical practice.